May 9, 2017 / 10:23 AM / 6 months ago

BRIEF-Gemphire reports Q1 loss per share of $0.79

May 9 (Reuters) - Gemphire Therapeutics Inc

* Gemphire announces first quarter 2017 financial results and provides corporate update

* Q1 loss per share $0.79

* Q1 earnings per share view $-0.65 -- Thomson Reuters I/B/E/S

* Expects full year operating expenses and cash used in operating activities to be approximately double 2016 levels

* Expect Q2 2017 operating expenses and cash used in operations to continue to be substantially above comparable prior period levels

* Top-line results from cobalt-1 phase 2B trial are expected in late June 2017

* Top-line results from royal-1 phase 2B trial are expected in Q3 of 2017

* Have plans to launch a phase 2 clinical development program in nash this year

* Top-line results from Indigo-1 phase 2B trial are targeted for Q1 of 2018 based on current pace of enrollment

* Plan to initiate phase 2 clinical development program (Azure-1) in nash in second half of 2017

* Cash and cash equivalents at March 31, 2017 totaled $29.3 million compared to $24.0 million at December 31, 2016

* Existing cash, net proceeds from private placement sufficient to fund operations through completion of ongoing dyslipidemia trials Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below